{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:14:00Z","timestamp":1788542040722,"version":"build-2803163510"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM122741"],"award-info":[{"award-number":["T32GM122741"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"crossref","award":["MRF\/2024900"],"award-info":[{"award-number":["MRF\/2024900"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["U24HG010615"],"award-info":[{"award-number":["U24HG010615"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["U24HG013077"],"award-info":[{"award-number":["U24HG013077"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40262-026-01673-x","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:18:28Z","timestamp":1784564308000},"page":"1295-1315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8771-1191","authenticated-orcid":false,"given":"Riley M.","family":"Randolph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9546-4768","authenticated-orcid":false,"given":"Sara","family":"Jubas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1739-8233","authenticated-orcid":false,"given":"Li","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-3290","authenticated-orcid":false,"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3096-6022","authenticated-orcid":false,"given":"Dhrita","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4145-7045","authenticated-orcid":false,"given":"Pamala A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-5308","authenticated-orcid":false,"given":"David","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3742-8863","authenticated-orcid":false,"given":"Daniel J.","family":"Crona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"3","key":"1673_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.anclin.2017.04.001","volume":"35","author":"CD Holt","year":"2017","unstructured":"Holt CD. Overview of immunosuppressive therapy in solid organ transplantation. Anesthesiol Clin. 2017;35(3):365\u201380. https:\/\/doi.org\/10.1016\/j.anclin.2017.04.001.","journal-title":"Anesthesiol Clin"},{"key":"1673_CR2","doi-asserted-by":"publisher","unstructured":"Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;(4):CD003961. https:\/\/doi.org\/10.1002\/14651858.CD003961.pub2.","DOI":"10.1002\/14651858.CD003961.pub2"},{"issue":"25","key":"1673_CR3","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562\u201375. https:\/\/doi.org\/10.1056\/NEJMoa067411.","journal-title":"N Engl J Med"},{"issue":"10","key":"1673_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353. https:\/\/doi.org\/10.2165\/00003088-200443100-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1673_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","volume":"63","author":"LJ Scott","year":"2003","unstructured":"Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63(12):1247\u201397. https:\/\/doi.org\/10.2165\/00003495-200363120-00006.","journal-title":"Drugs"},{"issue":"6","key":"1673_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404\u201330. https:\/\/doi.org\/10.2165\/00003088-199529060-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1673_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2133\/dmpk.22.328","volume":"22","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22(5):328\u201335. https:\/\/doi.org\/10.2133\/dmpk.22.328.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"1673_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/jps.10041","volume":"91","author":"S Tamura","year":"2002","unstructured":"Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci. 2002;91(3):719\u201329. https:\/\/doi.org\/10.1002\/jps.10041.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1673_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/01.ftd.0000170029.36573.a0","volume":"27","author":"H Zahir","year":"2005","unstructured":"Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit. 2005;27(4):422\u201330. https:\/\/doi.org\/10.1097\/01.ftd.0000170029.36573.a0.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"1673_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"U Christians","year":"2002","unstructured":"Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41(11):813\u201351. https:\/\/doi.org\/10.2165\/00003088-200241110-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1673_CR11","unstructured":"ASTELLAS. Prograf (tacrolimus) capsules, for oral use [package insert]. Published online September 14, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/050708s055,010115s007lbl.pdf. Accessed 7 Oct 2025."},{"issue":"1","key":"1673_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/tpj.2014.38","volume":"15","author":"L Rojas","year":"2015","unstructured":"Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenom J. 2015;15(1):38\u201348. https:\/\/doi.org\/10.1038\/tpj.2014.38.","journal-title":"Pharmacogenom J"},{"issue":"2","key":"1673_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.bbmt.2015.08.027","volume":"22","author":"SK Khaled","year":"2016","unstructured":"Khaled SK, Palmer JM, Herzog J, et al. Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus\/sirolimus blood levels and graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22(2):268\u201376. https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.027.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"1673_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-025-00363-4","volume":"25","author":"GDAR Naldi","year":"2025","unstructured":"Naldi GDAR, Minari AB, Pereira TDM, et al. CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus: a cohort study. Pharmacogenom J. 2025;25(2):4. https:\/\/doi.org\/10.1038\/s41397-025-00363-4.","journal-title":"Pharmacogenom J"},{"issue":"2","key":"1673_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-024-00325-2","volume":"24","author":"M Liu","year":"2024","unstructured":"Liu M, Hernandez S, Aquilante CL, et al. Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients. Pharmacogenom J. 2024;24(2):4. https:\/\/doi.org\/10.1038\/s41397-024-00325-2.","journal-title":"Pharmacogenom J"},{"key":"1673_CR16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3389\/fphar.2020.01142","volume":"11","author":"T van Gelder","year":"2020","unstructured":"van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes DJAR. The clinical impact of the C0\/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol. 2020;11:1142. https:\/\/doi.org\/10.3389\/fphar.2020.01142.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1673_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19\u201324. https:\/\/doi.org\/10.1002\/cpt.113.","journal-title":"Clin Pharmacol Ther"},{"key":"1673_CR18","unstructured":"DPWG. Pharmacogenetics. KNMP. Published online August 1, 2024. https:\/\/www.knmp.nl\/dossiers\/farmacogenetica\/pharmacogenetics. Accessed 24 Nov 2025."},{"issue":"11","key":"1673_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","volume":"55","author":"E Brooks","year":"2016","unstructured":"Brooks E, Tett SE, Isbel NM, Staatz CE. Population pharmacokinetic modelling and Bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2016;55(11):1295\u2013335. https:\/\/doi.org\/10.1007\/s40262-016-0396-1.","journal-title":"Clin Pharmacokinet"},{"key":"1673_CR20","unstructured":"US FDA, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry:\u00a0population pharmacokinetics. 2022;(FDA-2019-D-2398)."},{"key":"1673_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00358","volume":"8","author":"J-B Woillard","year":"2017","unstructured":"Woillard J-B, Mourad M, Neely M, et al. Tacrolimus updated guidelines through popPK modeling: how to benefit more from CYP3A pre-emptive genotyping prior to kidney transplantation. Front Pharmacol. 2017;8:358. https:\/\/doi.org\/10.3389\/fphar.2017.00358.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1673_CR22","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","volume":"99","author":"E St\u00f8rset","year":"2015","unstructured":"St\u00f8rset E, \u00c5sberg A, Skauby M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients: a prospective, randomized study. Transplantation. 2015;99(10):2158\u201366. https:\/\/doi.org\/10.1097\/TP.0000000000000708.","journal-title":"Transplantation"},{"issue":"1","key":"1673_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59739-6","volume":"16","author":"J Khong","year":"2025","unstructured":"Khong J, Lee M, Warren C, et al. Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: a phase 2 randomized clinical trial. Nat Commun. 2025;16(1):4558. https:\/\/doi.org\/10.1038\/s41467-025-59739-6.","journal-title":"Nat Commun"},{"issue":"4","key":"1673_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/bmt.2015.323","volume":"51","author":"A Ganetsky","year":"2016","unstructured":"Ganetsky A, Shah A, Miano TA, et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transpl. 2016;51(4):568\u201372. https:\/\/doi.org\/10.1038\/bmt.2015.323.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"1673_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bcp.12361","volume":"78","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset E, Holford N, Hennig S, et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol. 2014;78(3):509\u201323. https:\/\/doi.org\/10.1111\/bcp.12361.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1673_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/FTD.0000000000001289","volume":"47","author":"N Lloberas","year":"2025","unstructured":"Lloberas N, Vidal-Alabr\u00f3 A, Colom H. Customizing tacrolimus dosing in kidney transplantation: focus on pharmacogenetics. Ther Drug Monit. 2025;47(1):141\u201351. https:\/\/doi.org\/10.1097\/FTD.0000000000001289.","journal-title":"Ther Drug Monit"},{"key":"1673_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101752","volume":"55","author":"B Shi","year":"2023","unstructured":"Shi B, Liu Y, Liu D, et al. Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation. EClinicalMedicine. 2023;55:101752. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101752.","journal-title":"EClinicalMedicine."},{"issue":"9","key":"1673_CR28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40262-025-01533-0","volume":"64","author":"MI Francke","year":"2025","unstructured":"Francke MI, Sassen SDT, Lloberas N, et al. A population pharmacokinetic model and dosing algorithm to guide the tacrolimus starting and follow-up dose in living and deceased donor kidney transplant recipients. Clin Pharmacokinet. 2025;64(9):1379\u201394. https:\/\/doi.org\/10.1007\/s40262-025-01533-0.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1673_CR29","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.kint.2023.06.021","volume":"104","author":"N Lloberas","year":"2023","unstructured":"Lloberas N, Griny\u00f3 JM, Colom H, et al. A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian prediction. Kidney Int. 2023;104(4):840\u201350. https:\/\/doi.org\/10.1016\/j.kint.2023.06.021.","journal-title":"Kidney Int"},{"key":"1673_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","volume":"61","author":"AS Darwich","year":"2021","unstructured":"Darwich AS, Polasek TM, Aronson JK, et al. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu Rev Pharmacol Toxicol. 2021;61:225\u201345. https:\/\/doi.org\/10.1146\/annurev-pharmtox-033020-113257.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1673_CR31","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2024."},{"key":"1673_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105199","volume":"143","author":"L Huang","year":"2020","unstructured":"Huang L, Liu Y, Jiao Z, Wang J, Fang L, Mao J. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: a comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. Eur J Pharm Sci. 2020;143:105199. https:\/\/doi.org\/10.1016\/j.ejps.2019.105199.","journal-title":"Eur J Pharm Sci"},{"key":"1673_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107827","volume":"98","author":"L Li","year":"2021","unstructured":"Li L, Zhu M, Li D-Y, et al. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. Int Immunopharmacol. 2021;98:107827. https:\/\/doi.org\/10.1016\/j.intimp.2021.107827.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"1673_CR34","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1177\/0091270011423661","volume":"52","author":"FT Musuamba","year":"2012","unstructured":"Musuamba FT, Mourad M, Haufroid V, et al. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol. 2012;52(12):1833\u201343. https:\/\/doi.org\/10.1177\/0091270011423661.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1673_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jcpt.12599","volume":"42","author":"B Chen","year":"2017","unstructured":"Chen B, Shi HQ, Liu XX, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther. 2017;42(6):679\u201388. https:\/\/doi.org\/10.1111\/jcpt.12599.","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"1673_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40262-013-0069-2","volume":"52","author":"K Ogasawara","year":"2013","unstructured":"Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2\/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52(9):751\u201362. https:\/\/doi.org\/10.1007\/s40262-013-0069-2.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1673_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2579-6","volume":"36","author":"T Lu","year":"2019","unstructured":"Lu T, Zhu X, Xu S, et al. Dosage optimization based on population pharmacokinetic analysis of tacrolimus in Chinese patients with nephrotic syndrome. Pharm Res. 2019;36(3):45. https:\/\/doi.org\/10.1007\/s11095-019-2579-6.","journal-title":"Pharm Res"},{"issue":"11","key":"1673_CR38","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cpdd.971","volume":"10","author":"Y Lu","year":"2021","unstructured":"Lu Y, Xu L, Cui J, Shen S, Li X. Effects of postoperative day and NR1I2 on tacrolimus clearance in Chinese liver transplant recipients: a population model approach. Clin Pharmacol Drug Dev. 2021;10(11):1385\u201394. https:\/\/doi.org\/10.1002\/cpdd.971.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1673_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.942129","volume":"13","author":"Q Huang","year":"2022","unstructured":"Huang Q, Lin X, Wang Y, et al. Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: a combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction. Front Pharmacol. 2022;13:942129. https:\/\/doi.org\/10.3389\/fphar.2022.942129.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1673_CR40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/jcph.1823","volume":"61","author":"M Al-Kofahi","year":"2021","unstructured":"Al-Kofahi M, Oetting WS, Schladt DP, et al. Precision dosing for tacrolimus using genotypes and clinical factors in kidney transplant recipients of European ancestry. J Clin Pharmacol. 2021;61(8):1035\u201344. https:\/\/doi.org\/10.1002\/jcph.1823.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1673_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/tpj.2015.87","volume":"17","author":"K Sanghavi","year":"2017","unstructured":"Sanghavi K, Brundage RC, Miller MB, et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenom J. 2017;17(1):61\u20138. https:\/\/doi.org\/10.1038\/tpj.2015.87.","journal-title":"Pharmacogenom J"},{"issue":"6","key":"1673_CR42","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1365-2125.2011.04039.x","volume":"72","author":"C Passey","year":"2011","unstructured":"Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948\u201357. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04039.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1673_CR43","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2165\/11535950-000000000-00000","volume":"49","author":"K Benkali","year":"2010","unstructured":"Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 2010;49(10):683\u201392. https:\/\/doi.org\/10.2165\/11535950-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1673_CR44","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1111\/bcp.14842","volume":"87","author":"LC Martial","year":"2021","unstructured":"Martial LC, Biewenga M, Ruijter BN, et al. Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. Br J Clin Pharmacol. 2021;87(11):4262\u201372. https:\/\/doi.org\/10.1111\/bcp.14842.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1673_CR45","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1111\/bcp.15857","volume":"89","author":"A Paschier","year":"2023","unstructured":"Paschier A, Destere A, Monchaud C, Labriffe M, Marquet P, Woillard J-B. Tacrolimus population pharmacokinetics in adult heart transplant patients. Br J Clin Pharmacol. 2023;89(12):3584\u201395. https:\/\/doi.org\/10.1111\/bcp.15857.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1673_CR46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","volume":"71","author":"J-B Woillard","year":"2011","unstructured":"Woillard J-B, de Winter BCM, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations: twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71(3):391\u2013402. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03837.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1673_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","volume":"51","author":"C Monchaud","year":"2012","unstructured":"Monchaud C, de Winter BC, Knoop C, et al. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 2012;51(3):175\u201386. https:\/\/doi.org\/10.2165\/11594760-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1673_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.542","volume":"11","author":"L Huang","year":"2021","unstructured":"Huang L, Assiri AA, Wen P, et al. The CYP3A5 genotypes of both liver transplant recipients and donors influence the time-dependent recovery of tacrolimus clearance during the early stage following transplantation. Clin Transl Med. 2021;11(10):e542. https:\/\/doi.org\/10.1002\/ctm2.542.","journal-title":"Clin Transl Med"},{"key":"1673_CR49","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/TCRM.S184376","volume":"14","author":"E Ji","year":"2018","unstructured":"Ji E, Kim MG, Oh JM. CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag. 2018;14:2119\u201326. https:\/\/doi.org\/10.2147\/TCRM.S184376.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"1673_CR50","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007;32(5):505\u201315. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00850.x.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1673_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","volume":"72","author":"DJAR Moes","year":"2016","unstructured":"Moes DJAR, van der Bent SAS, Swen JJ, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol. 2016;72(2):163\u201374. https:\/\/doi.org\/10.1007\/s00228-015-1963-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1673_CR52","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1060028019897050","volume":"54","author":"J Shao","year":"2020","unstructured":"Shao J, Wang C, Fu P, Chen F, Zhang Y, Wei J. Impact of donor and recipient CYP3A5*3 genotype on tacrolimus population pharmacokinetics in Chinese adult liver transplant recipients. Ann Pharmacother. 2020;54(7):652\u201361. https:\/\/doi.org\/10.1177\/1060028019897050.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1673_CR53","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.3390\/pharmaceutics15122699","volume":"15","author":"Z Mohammed Ali","year":"2023","unstructured":"Mohammed Ali Z, Meertens M, Fern\u00e1ndez B, et al. CYP3A5*3 and CYP3A4*22 cluster polymorphism effects on LCP-Tac tacrolimus exposure: population pharmacokinetic approach. Pharmaceutics. 2023;15(12):2699. https:\/\/doi.org\/10.3390\/pharmaceutics15122699.","journal-title":"Pharmaceutics"},{"issue":"8","key":"1673_CR54","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","volume":"56","author":"F Andreu","year":"2017","unstructured":"Andreu F, Colom H, Elens L, et al. A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach. Clin Pharmacokinet. 2017;56(8):963\u201375. https:\/\/doi.org\/10.1007\/s40262-016-0491-3.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1673_CR55","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/jcph.1118","volume":"58","author":"O Campagne","year":"2018","unstructured":"Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. Tacrolimus population pharmacokinetics and multiple CYP3A5 genotypes in black and white renal transplant recipients. J Clin Pharmacol. 2018;58(9):1184\u201395. https:\/\/doi.org\/10.1002\/jcph.1118.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1673_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00228-012-1296-4","volume":"69","author":"N Han","year":"2013","unstructured":"Han N, Yun H, Hong J, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(1):53\u201363. https:\/\/doi.org\/10.1007\/s00228-012-1296-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1673_CR57","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/bcp.12649","volume":"80","author":"CO Jacobo-Cabral","year":"2015","unstructured":"Jacobo-Cabral CO, Garc\u00eda-Roca P, Romero-Tejeda EM, et al. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. Br J Clin Pharmacol. 2015;80(4):630\u201341. https:\/\/doi.org\/10.1111\/bcp.12649.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1673_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcpt.13138","volume":"124","author":"JE Res\u00e9ndiz-Galv\u00e1n","year":"2019","unstructured":"Res\u00e9ndiz-Galv\u00e1n JE, Medell\u00edn-Garibay SE, Mil\u00e1n-Segovia RDC, Ni\u00f1o-Moreno PDC, Isordia-Segovia J, Romano-Moreno S. Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant. Basic Clin Pharmacol Toxicol. 2019;124(3):303\u201311. https:\/\/doi.org\/10.1111\/bcpt.13138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"1673_CR59","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/00498254.2022.2064252","volume":"52","author":"S-F Zhang","year":"2022","unstructured":"Zhang S-F, Tang B-H, Wei A-H, Du Y, Guan Z-W, Li Y. Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes. Xenobiotica. 2022;52(3):312\u201321. https:\/\/doi.org\/10.1080\/00498254.2022.2064252.","journal-title":"Xenobiotica"},{"issue":"4","key":"1673_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13318-020-00609-5","volume":"45","author":"J Liu","year":"2020","unstructured":"Liu J, Guo Y-P, Jiao Z, et al. Population pharmacokinetic analysis of tacrolimus in adult Chinese patients with myasthenia gravis: a prospective study. Eur J Drug Metab Pharmacokinet. 2020;45(4):453\u201366. https:\/\/doi.org\/10.1007\/s13318-020-00609-5.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1673_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-025-03920-9","author":"S Zhou","year":"2025","unstructured":"Zhou S, Lian Q, Luo H, et al. Population pharmacokinetic characteristics of tacrolimus in Chinese lung transplant recipients and optimisation of dosing regimen during the early post-transplantation phase. Eur J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00228-025-03920-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1673_CR62","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2710.2010.01206.x","volume":"36","author":"XJ Shi","year":"2011","unstructured":"Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther. 2011;36(5):614\u201324. https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01206.x.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"1673_CR63","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/bcp.13838","volume":"85","author":"LM Andrews","year":"2019","unstructured":"Andrews LM, Hesselink DA, van Schaik RHN, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85(3):601\u201315. https:\/\/doi.org\/10.1111\/bcp.13838.","journal-title":"Br J Clin Pharmacol"},{"key":"1673_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115000","volume":"396","author":"I Hannachi","year":"2020","unstructured":"Hannachi I, Ben Fredj N, Chadli Z, et al. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant. Toxicol Appl Pharmacol. 2020;396:115000. https:\/\/doi.org\/10.1016\/j.taap.2020.115000.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"1673_CR65","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jcph.2156","volume":"63","author":"Z-R Li","year":"2023","unstructured":"Li Z-R, Li R-D, Niu W-J, et al. Population pharmacokinetic modeling combined with machine learning approach improved tacrolimus trough concentration prediction in Chinese adult liver transplant recipients. J Clin Pharmacol. 2023;63(3):314\u201325. https:\/\/doi.org\/10.1002\/jcph.2156.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1673_CR66","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jcpt.12523","volume":"42","author":"HJ Zhang","year":"2017","unstructured":"Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017;42(4):425\u201332. https:\/\/doi.org\/10.1111\/jcpt.12523.","journal-title":"J Clin Pharm Ther"},{"issue":"13","key":"1673_CR67","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/pgs-2017-0139","volume":"19","author":"W Zhu","year":"2018","unstructured":"Zhu W, Xue L, Peng H, et al. Tacrolimus population pharmacokinetic models according to CYP3A5\/CYP3A4\/POR genotypes in Chinese Han renal transplant patients. Pharmacogenomics. 2018;19(13):1013\u201325. https:\/\/doi.org\/10.2217\/pgs-2017-0139.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"1673_CR68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","volume":"36","author":"TK Bergmann","year":"2014","unstructured":"Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2014;36(1):62\u201370. https:\/\/doi.org\/10.1097\/FTD.0b013e31829f1ab8.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1673_CR69","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bcpt.12176","volume":"114","author":"N Han","year":"2014","unstructured":"Han N, Ha S, Yun H, et al. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol. 2014;114(5):400\u20136. https:\/\/doi.org\/10.1111\/bcpt.12176.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"1673_CR70","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/jcpt.13407","volume":"46","author":"Y Jing","year":"2021","unstructured":"Jing Y, Kong Y, Hou X, et al. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. J Clin Pharm Ther. 2021;46(4):1117\u201328. https:\/\/doi.org\/10.1111\/jcpt.13407.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"1673_CR71","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/00498254.2020.1774682","volume":"50","author":"J Ling","year":"2020","unstructured":"Ling J, Dong L-L, Yang X-P, et al. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation. Xenobiotica. 2020;50(12):1501\u20139. https:\/\/doi.org\/10.1080\/00498254.2020.1774682.","journal-title":"Xenobiotica"},{"issue":"2","key":"1673_CR72","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/bdd.2311","volume":"43","author":"F Teng","year":"2022","unstructured":"Teng F, Zhang W, Wang W, et al. Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Biopharm Drug Dispos. 2022;43(2):76\u201385. https:\/\/doi.org\/10.1002\/bdd.2311.","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"1673_CR73","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","volume":"45","author":"L Zhu","year":"2015","unstructured":"Zhu L, Yang J, Zhang Y, Jing Y, Zhang Y, Li G. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Xenobiotica. 2015;45(9):840\u20136. https:\/\/doi.org\/10.3109\/00498254.2015.1021733.","journal-title":"Xenobiotica"},{"key":"1673_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105448","volume":"152","author":"X Cai","year":"2020","unstructured":"Cai X, Song H, Jiao Z, et al. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. Eur J Pharm Sci. 2020;152:105448. https:\/\/doi.org\/10.1016\/j.ejps.2020.105448.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"1673_CR75","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","volume":"57","author":"LM Andrews","year":"2018","unstructured":"Andrews LM, Hesselink DA, van Gelder T, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation. Clin Pharmacokinet. 2018;57(4):475\u201389. https:\/\/doi.org\/10.1007\/s40262-017-0567-8.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1673_CR76","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40262-016-0390-7","volume":"55","author":"AA Prytu\u0142a","year":"2016","unstructured":"Prytu\u0142a AA, Cransberg K, Bouts AHM, et al. The effect of weight and CYP3A5 genotype on the population pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. Clin Pharmacokinet. 2016;55(9):1129\u201343. https:\/\/doi.org\/10.1007\/s40262-016-0390-7.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1673_CR77","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/clpt.2009.210","volume":"86","author":"W Zhao","year":"2009","unstructured":"Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86(6):609\u201318. https:\/\/doi.org\/10.1038\/clpt.2009.210.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1673_CR78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","volume":"23","author":"X Zuo","year":"2013","unstructured":"Zuo X, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom. 2013;23(5):251\u201361. https:\/\/doi.org\/10.1097\/FPC.0b013e32835fcbb6.","journal-title":"Pharmacogenet Genom"},{"issue":"2","key":"1673_CR79","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3892\/etm.2020.8821","volume":"20","author":"X Chen","year":"2020","unstructured":"Chen X, Wang D-D, Xu H, Li Z-P. Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real-world data. Exp Ther Med. 2020;20(2):1423\u201330. https:\/\/doi.org\/10.3892\/etm.2020.8821.","journal-title":"Exp Ther Med"},{"issue":"5","key":"1673_CR80","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/FTD.0000000000001008","volume":"44","author":"M Liao","year":"2022","unstructured":"Liao M, Wang M, Zhu X, Zhao L, Zhao M. Tacrolimus population pharmacokinetic model in adult Chinese patients with nephrotic syndrome and dosing regimen identification using Monte Carlo simulations. Ther Drug Monit. 2022;44(5):615\u201324. https:\/\/doi.org\/10.1097\/FTD.0000000000001008.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1673_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47876-0","volume":"9","author":"JH Kim","year":"2019","unstructured":"Kim JH, Han N, Kim MG, et al. Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients. Sci Rep. 2019;9(1):11740. https:\/\/doi.org\/10.1038\/s41598-019-47876-0.","journal-title":"Sci Rep"},{"issue":"1","key":"1673_CR82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/pgs-2018-0116","volume":"20","author":"Y Han","year":"2019","unstructured":"Han Y, Zhou H, Cai J, et al. Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. Pharmacogenomics. 2019;20(1):21\u201335. https:\/\/doi.org\/10.2217\/pgs-2018-0116.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"1673_CR83","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/jcpt.13072","volume":"45","author":"X Chen","year":"2020","unstructured":"Chen X, Wang D, Xu H, Li Z. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule. J Clin Pharm Ther. 2020;45(2):309\u201317. https:\/\/doi.org\/10.1111\/jcpt.13072.","journal-title":"J Clin Pharm Ther"},{"issue":"Pt A","key":"1673_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110866","volume":"124","author":"C-B Wang","year":"2023","unstructured":"Wang C-B, Zhang Y-J, Zhao M-M, Zhao L. Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus. Int Immunopharmacol. 2023;124(Pt A):110866. https:\/\/doi.org\/10.1016\/j.intimp.2023.110866.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"1673_CR85","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-024-01414-y","volume":"63","author":"Y Hoffert","year":"2024","unstructured":"Hoffert Y, Dia N, Vanuytsel T, et al. Model-informed precision dosing of tacrolimus: a systematic review of population pharmacokinetic models and a benchmark study of software tools. Clin Pharmacokinet. 2024;63(10):1407\u201321. https:\/\/doi.org\/10.1007\/s40262-024-01414-y.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1673_CR86","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/psp4.12392","volume":"8","author":"C Emoto","year":"2019","unstructured":"Emoto C, Johnson TN, Hahn D, et al. A theoretical physiologically-based pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition. CPT Pharmacomet Syst Pharmacol. 2019;8(5):273\u201384. https:\/\/doi.org\/10.1002\/psp4.12392.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"11","key":"1673_CR87","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00228-018-2521-6","volume":"74","author":"C Hu","year":"2018","unstructured":"Hu C, Yin W-J, Li D-Y, et al. Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes. Eur J Clin Pharmacol. 2018;74(11):1437\u201347. https:\/\/doi.org\/10.1007\/s00228-018-2521-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1673_CR88","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bcp.15909","volume":"90","author":"K Khamlek","year":"2024","unstructured":"Khamlek K, Komenkul V, Sriboonruang T, Wattanavijitkul T. Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: a systematic review. Br J Clin Pharmacol. 2024;90(2):406\u201326. https:\/\/doi.org\/10.1111\/bcp.15909.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1673_CR89","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet. 2020;59(11):1357\u201392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x.","journal-title":"Clin Pharmacokinet"},{"key":"1673_CR90","volume-title":"StatPearls","author":"RD Rosen","year":"2025","unstructured":"Rosen RD, Singh A, Burns B. Organ procurement from patients with trauma. In: StatPearls. StatPearls Publishing, Treasure Island, Florida. 2025."},{"issue":"3","key":"1673_CR91","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamasurg.2014.2038","volume":"150","author":"A Rana","year":"2015","unstructured":"Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2014.2038.","journal-title":"JAMA Surg"},{"issue":"11","key":"1673_CR92","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40262-025-01529-w","volume":"64","author":"TC Dunlap","year":"2025","unstructured":"Dunlap TC, Zhu J, Weiner DL, et al. A tacrolimus population pharmacokinetic model for adult allogeneic hematopoietic cell transplant recipients provides clinical opportunities for precision dosing. Clin Pharmacokinet. 2025;64(11):1621\u201337. https:\/\/doi.org\/10.1007\/s40262-025-01529-w.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1673_CR93","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/FPC.0b013e3282f9ac01","volume":"18","author":"M Fukudo","year":"2008","unstructured":"Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genom. 2008;18(5):413\u201323. https:\/\/doi.org\/10.1097\/FPC.0b013e3282f9ac01.","journal-title":"Pharmacogenet Genom"},{"issue":"3","key":"1673_CR94","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307. https:\/\/doi.org\/10.1097\/FTD.0000000000000640.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"1673_CR95","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/tri.12194","volume":"26","author":"A \u00c5sberg","year":"2013","unstructured":"\u00c5sberg A, Midtvedt K, van Guilder M, et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int. 2013;26(12):1198\u2013207. https:\/\/doi.org\/10.1111\/tri.12194.","journal-title":"Transpl Int"},{"key":"1673_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106188","volume":"80","author":"J Liu","year":"2020","unstructured":"Liu J, Chen D, Yao B, et al. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients. Int Immunopharmacol. 2020;80:106188. https:\/\/doi.org\/10.1016\/j.intimp.2020.106188.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"1673_CR97","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/bcp.14034","volume":"85","author":"JK Coller","year":"2019","unstructured":"Coller JK, Ramachandran J, John L, Tuke J, Wigg A, Doogue M. The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome. Br J Clin Pharmacol. 2019;85(9):2170\u20135. https:\/\/doi.org\/10.1111\/bcp.14034.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1673_CR98","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/jlts.2002.31654","volume":"8","author":"J-N Vauthey","year":"2002","unstructured":"Vauthey J-N, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233\u201340. https:\/\/doi.org\/10.1053\/jlts.2002.31654.","journal-title":"Liver Transpl"},{"issue":"1","key":"1673_CR99","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cts.13142","volume":"15","author":"KE Kvitne","year":"2022","unstructured":"Kvitne KE, Robertsen I, Skovlund E, et al. Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed controlled trial. Clin Transl Sci. 2022;15(1):221\u201333. https:\/\/doi.org\/10.1111\/cts.13142.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"1673_CR100","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00228-022-03336-9","volume":"78","author":"K Eide Kvitne","year":"2022","unstructured":"Eide Kvitne K, Hole K, Krogstad V, et al. Correlations between 4\u03b2-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. Eur J Clin Pharmacol. 2022;78(8):1289\u201399. https:\/\/doi.org\/10.1007\/s00228-022-03336-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1673_CR101","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00044-024-03360-7","volume":"33","author":"M Vander Schaaf","year":"2024","unstructured":"Vander Schaaf M, Luth K, Townsend DM, et al. CYP3A4 drug metabolism considerations in pediatric pharmacotherapy. Med Chem Res. 2024;33(12):2221\u201335. https:\/\/doi.org\/10.1007\/s00044-024-03360-7.","journal-title":"Med Chem Res"},{"issue":"9","key":"1673_CR102","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/psp4.13192","volume":"13","author":"TN Johnson","year":"2024","unstructured":"Johnson TN, Batchelor HK, Goelen J, Horniblow RD, Dinh J. Combining data on the bioavailability of midazolam and physiologically-based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny. CPT Pharmacometr Syst Pharmacol. 2024;13(9):1570\u201381. https:\/\/doi.org\/10.1002\/psp4.13192.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"1673_CR103","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MOG.0000000000000176","volume":"31","author":"IH Kim","year":"2015","unstructured":"Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31(3):184\u201391. https:\/\/doi.org\/10.1097\/MOG.0000000000000176.","journal-title":"Curr Opin Gastroenterol"},{"issue":"10","key":"1673_CR104","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1111\/cts.13571","volume":"16","author":"A Alghamdi","year":"2023","unstructured":"Alghamdi A, Seay S, Hooper DK, et al. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients. Clin Transl Sci. 2023;16(10):1768\u201378. https:\/\/doi.org\/10.1111\/cts.13571.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1673_CR105","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cts.13495","volume":"16","author":"KM Tornatore","year":"2023","unstructured":"Tornatore KM, Attwood K, Venuto RC, Murray B. Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: implications for health inequities. Clin Transl Sci. 2023;16(5):861\u201371. https:\/\/doi.org\/10.1111\/cts.13495.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1673_CR106","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/bcp.12729","volume":"80","author":"CE Staatz","year":"2015","unstructured":"Staatz CE, St\u00f8rset E, Bergmann TK, Hennig S, Holford N. Tacrolimus pharmacokinetics after kidney transplantation: influence of changes in haematocrit and steroid dose. Br J Clin Pharmacol. 2015;80(6):1475\u20136. https:\/\/doi.org\/10.1111\/bcp.12729.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1673_CR107","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2165\/00003088-200443110-00005","volume":"43","author":"DRJ Kuypers","year":"2004","unstructured":"Kuypers DRJ, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43(11):741\u201362. https:\/\/doi.org\/10.2165\/00003088-200443110-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1673_CR108","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bcp.12703","volume":"80","author":"H de Jonge","year":"2015","unstructured":"de Jonge H, Vanhove T, de Loor H, Verbeke K, Kuypers DRJ. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol. 2015;80(3):548\u201359. https:\/\/doi.org\/10.1111\/bcp.12703.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1673_CR109","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00467-018-4117-x","volume":"34","author":"AM Schijvens","year":"2019","unstructured":"Schijvens AM, van Hesteren FHS, Cornelissen EAM, et al. The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatr Nephrol. 2019;34(3):507\u201315. https:\/\/doi.org\/10.1007\/s00467-018-4117-x.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1673_CR110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset E, Holford N, Midtvedt K, Bremer S, Bergan S, \u00c5sberg A. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70(1):65\u201377. https:\/\/doi.org\/10.1007\/s00228-013-1584-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1673_CR111","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","volume":"57","author":"WJ Jusko","year":"1995","unstructured":"Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57(3):281\u201390. https:\/\/doi.org\/10.1016\/0009-9236(95)90153-1.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1673_CR112","first-page":"610","volume":"25","author":"FS Chow","year":"1997","unstructured":"Chow FS, Piekoszewski W, Jusko WJ. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos. 1997;25(5):610\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"37","key":"1673_CR113","doi-asserted-by":"publisher","first-page":"38379","DOI":"10.1074\/jbc.M404949200","volume":"279","author":"O Burk","year":"2004","unstructured":"Burk O, Koch I, Raucy J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004;279(37):38379\u201385. https:\/\/doi.org\/10.1074\/jbc.M404949200.","journal-title":"J Biol Chem"},{"issue":"5","key":"1673_CR114","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1172\/JCI3703","volume":"102","author":"JM Lehmann","year":"1998","unstructured":"Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102(5):1016\u201323. https:\/\/doi.org\/10.1172\/JCI3703.","journal-title":"J Clin Invest"},{"issue":"9","key":"1673_CR115","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/ndt\/gfy096","volume":"33","author":"F Stifft","year":"2018","unstructured":"Stifft F, van Kuijk SMJ, Bekers O, Christiaans MHL. Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients. Nephrol Dial Transpl. 2018;33(9):1668\u201375. https:\/\/doi.org\/10.1093\/ndt\/gfy096.","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"1673_CR116","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","volume":"18","author":"D Anglicheau","year":"2003","unstructured":"Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transpl. 2003;18(11):2409\u201314. https:\/\/doi.org\/10.1093\/ndt\/gfg381.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"1673_CR117","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1399-3046.2005.00263.x","volume":"9","author":"JS Kim","year":"2005","unstructured":"Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti VV. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transpl. 2005;9(2):162\u20139. https:\/\/doi.org\/10.1111\/j.1399-3046.2005.00263.x.","journal-title":"Pediatr Transpl"},{"issue":"10","key":"1673_CR118","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00147-003-0615-1","volume":"16","author":"EM van Duijnhoven","year":"2003","unstructured":"van Duijnhoven EM, Boots JMM, Christiaans MHL, Stolk LML, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003;16(10):721\u20135. https:\/\/doi.org\/10.1007\/s00147-003-0615-1.","journal-title":"Transpl Int"},{"issue":"4","key":"1673_CR119","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/s0041-1345(98)00234-6","volume":"30","author":"NA Undre","year":"1998","unstructured":"Undre NA, Sch\u00e4fer A, European Tacrolimus Multicentre Renal Study Group. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. Transpl Proc. 1998;30(4):1261\u20133. https:\/\/doi.org\/10.1016\/s0041-1345(98)00234-6.","journal-title":"Transpl Proc"},{"issue":"11","key":"1673_CR120","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1111\/bcp.16172","volume":"90","author":"A Saqr","year":"2024","unstructured":"Saqr A, Al-Kofahi M, Mohamed M, et al. Steroid-tacrolimus drug-drug interaction and the effect of CYP3A genotypes. Br J Clin Pharmacol. 2024;90(11):2837\u201348. https:\/\/doi.org\/10.1111\/bcp.16172.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1673_CR121","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1472-8206.2008.00644.x","volume":"23","author":"S-I Park","year":"2009","unstructured":"Park S-I, Felipe CR, Pinheiro-Machado PG, et al. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol. 2009;23(1):137\u201345. https:\/\/doi.org\/10.1111\/j.1472-8206.2008.00644.x.","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"1673_CR122","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1600-6143.2012.04327.x","volume":"13","author":"FS Shihab","year":"2013","unstructured":"Shihab FS, Lee ST, Smith LD, et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. Am J Transpl. 2013;13(2):474\u201384. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04327.x.","journal-title":"Am J Transpl"},{"issue":"3","key":"1673_CR123","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.0306-5251.2003.01882.x","volume":"56","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol. 2003;56(3):327\u201330. https:\/\/doi.org\/10.1046\/j.0306-5251.2003.01882.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1673_CR124","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/clinchem\/42.9.1426","volume":"42","author":"AK Gonschior","year":"1996","unstructured":"Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem. 1996;42(9):1426\u201332.","journal-title":"Clin Chem"},{"issue":"12","key":"1673_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122739","volume":"14","author":"Y-C Zhao","year":"2022","unstructured":"Zhao Y-C, Xiao C-L, Hou J-J, et al. The effect of voriconazole on tacrolimus in kidney transplantation recipients: a real-world study. Pharmaceutics. 2022;14(12):2739. https:\/\/doi.org\/10.3390\/pharmaceutics14122739.","journal-title":"Pharmaceutics"},{"key":"1673_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1502097","volume":"15","author":"Z-H Sun","year":"2024","unstructured":"Sun Z-H, Zhao Y-C, Li J-K, et al. Population dynamics analysis of the interaction between tacrolimus and voriconazole in renal transplant recipients. Front Pharmacol. 2024;15:1502097. https:\/\/doi.org\/10.3389\/fphar.2024.1502097.","journal-title":"Front Pharmacol"},{"key":"1673_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1458838","volume":"15","author":"H Zong","year":"2024","unstructured":"Zong H, Zhang Y, Liu F, et al. Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients. Front Pharmacol. 2024;15:1458838. https:\/\/doi.org\/10.3389\/fphar.2024.1458838.","journal-title":"Front Pharmacol"},{"key":"1673_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.692922","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang Y, Huang X, Shi Y, et al. CYP3A5 genotype-dependent drug-drug interaction between tacrolimus and nifedipine in Chinese renal transplant patients. Front Pharmacol. 2021;12:692922. https:\/\/doi.org\/10.3389\/fphar.2021.692922.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1673_CR129","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jpba.2010.02.003","volume":"52","author":"H Wei","year":"2010","unstructured":"Wei H, Xu W, Cai F, et al. Simultaneous determination of five lignan constituents of Wuzhi capsule in rat plasma by LC-MS\/MS: application to pharmacokinetic study. J Pharm Biomed Anal. 2010;52(5):741\u20136. https:\/\/doi.org\/10.1016\/j.jpba.2010.02.003.","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"1673_CR130","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1124\/dmd.112.050302","volume":"41","author":"H Wei","year":"2013","unstructured":"Wei H, Tao X, Di P, et al. Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. Drug Metab Dispos. 2013;41(7):1398\u2013403. https:\/\/doi.org\/10.1124\/dmd.112.050302.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1673_CR131","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1124\/dmd.114.062067","volume":"43","author":"X Fan","year":"2015","unstructured":"Fan X, Chen P, Jiang Y, et al. Therapeutic efficacy of Wuzhi tablet (Schisandra sphenanthera extract) on acetaminophen-induced hepatotoxicity through a mechanism distinct from N-acetylcysteine. Drug Metab Dispos. 2015;43(3):317\u201324. https:\/\/doi.org\/10.1124\/dmd.114.062067.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1673_CR132","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00228-011-1075-7","volume":"67","author":"H-W Xin","year":"2011","unstructured":"Xin H-W, Li Q, Wu X-C, et al. Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients. Eur J Clin Pharmacol. 2011;67(12):1309\u201311. https:\/\/doi.org\/10.1007\/s00228-011-1075-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1673_CR133","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2125.2007.02922.x","volume":"64","author":"H-W Xin","year":"2007","unstructured":"Xin H-W, Wu X-C, Li Q, et al. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol. 2007;64(4):469\u201375. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02922.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1-2","key":"1673_CR134","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijpharm.2010.01.025","volume":"389","author":"XL Qin","year":"2010","unstructured":"Qin XL, Bi HC, Wang XD, et al. Mechanistic understanding of the different effects of Wuzhi tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of tacrolimus (FK506). Int J Pharm. 2010;389(1\u20132):114\u201321. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.01.025.","journal-title":"Int J Pharm"},{"issue":"5","key":"1673_CR135","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00498254.2019.1669844","volume":"50","author":"X Chen","year":"2020","unstructured":"Chen X, Wang D-D, Xu H, Li Z-P. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule. Xenobiotica. 2020;50(5):606\u201313. https:\/\/doi.org\/10.1080\/00498254.2019.1669844.","journal-title":"Xenobiotica"},{"issue":"8","key":"1673_CR136","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/bcp.13605","volume":"84","author":"G-X Hao","year":"2018","unstructured":"Hao G-X, Huang X, Zhang D-F, et al. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. Br J Clin Pharmacol. 2018;84(8):1748\u201356. https:\/\/doi.org\/10.1111\/bcp.13605.","journal-title":"Br J Clin Pharmacol"},{"issue":"D1","key":"1673_CR137","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gkz836","volume":"48","author":"S Fairley","year":"2020","unstructured":"Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample Resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res. 2020;48(D1):D941\u20137. https:\/\/doi.org\/10.1093\/nar\/gkz836.","journal-title":"Nucleic Acids Res"},{"issue":"7993","key":"1673_CR138","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024;625(7993):92\u2013100. https:\/\/doi.org\/10.1038\/s41586-023-06045-0.","journal-title":"Nature"},{"issue":"3","key":"1673_CR139","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/00912700122010104","volume":"41","author":"I Bekersky","year":"2001","unstructured":"Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol. 2001;41(3):289\u201397. https:\/\/doi.org\/10.1177\/00912700122010104.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1673_CR140","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/00912700122009999","volume":"41","author":"I Bekersky","year":"2001","unstructured":"Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol. 2001;41(2):176\u201382. https:\/\/doi.org\/10.1177\/00912700122009999.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1673_CR141","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1034\/j.1399-0012.2001.150504.x","volume":"15","author":"M Kimikawa","year":"2001","unstructured":"Kimikawa M, Kamoya K, Toma H, Teraoka S. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transpl. 2001;15(5):324\u20139. https:\/\/doi.org\/10.1034\/j.1399-0012.2001.150504.x.","journal-title":"Clin Transpl"},{"issue":"5-6","key":"1673_CR142","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000331856","volume":"88","author":"L Xue","year":"2011","unstructured":"Xue L, Zhang H, Ma S, Rui J-Z, Miao L-Y. Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers. Pharmacology. 2011;88(5\u20136):288\u201394. https:\/\/doi.org\/10.1159\/000331856.","journal-title":"Pharmacology"},{"issue":"1","key":"1673_CR143","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/FTD.0000000000001147","volume":"46","author":"A Abderahmene","year":"2024","unstructured":"Abderahmene A, Francke MI, Andrews LM, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus for Tunisian adults after renal transplantation. Ther Drug Monit. 2024;46(1):57\u201366. https:\/\/doi.org\/10.1097\/FTD.0000000000001147.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1673_CR144","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bcp.16277","volume":"91","author":"K Agergaard","year":"2025","unstructured":"Agergaard K, Thiesson HC, Carstens J, et al. Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney-transplanted patients. Br J Clin Pharmacol. 2025;91(3):761\u201373. https:\/\/doi.org\/10.1111\/bcp.16277.","journal-title":"Br J Clin Pharmacol"},{"key":"1673_CR145","doi-asserted-by":"publisher","first-page":"1456565","DOI":"10.3389\/fphar.2024.1456565","volume":"15","author":"B Fern\u00e1ndez-Alarc\u00f3n","year":"2024","unstructured":"Fern\u00e1ndez-Alarc\u00f3n B, Nolberger O, Vidal-Alabr\u00f3 A, et al. Guiding the starting dose of the once-daily formulation of tacrolimus in \u201cde novo\u201d adult renal transplant patients: a population approach. Front Pharmacol. 2024;15:1456565. https:\/\/doi.org\/10.3389\/fphar.2024.1456565.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1673_CR146","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1007\/s12325-021-01905-5","volume":"38","author":"E Henin","year":"2021","unstructured":"Henin E, Govoni M, Cella M, Laveille C, Piotti G. Therapeutic drug monitoring strategies for envarsus in de novo kidney transplant patients using population modelling and simulations. Adv Ther. 2021;38(10):5317\u201332. https:\/\/doi.org\/10.1007\/s12325-021-01905-5.","journal-title":"Adv Ther"},{"issue":"2","key":"1673_CR147","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","volume":"31","author":"RR Press","year":"2009","unstructured":"Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31(2):187\u201397. https:\/\/doi.org\/10.1097\/FTD.0b013e31819c3d6d.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1673_CR148","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/biomedicines13061501","volume":"13","author":"CA Rotarescu","year":"2025","unstructured":"Rotarescu CA, Maruntelu I, Rotarescu I, Constantinescu A-E, Constantinescu I. Analysis of tacrolimus clearance in patients with kidney transplants from Romania. Biomedicines. 2025;13(6):1501. https:\/\/doi.org\/10.3390\/biomedicines13061501.","journal-title":"Biomedicines."},{"issue":"2","key":"1673_CR149","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00228-012-1330-6","volume":"69","author":"W Zhao","year":"2013","unstructured":"Zhao W, Fakhoury M, Baudouin V, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(2):189\u201395. https:\/\/doi.org\/10.1007\/s00228-012-1330-6.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01673-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01673-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01673-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:23:25Z","timestamp":1788539005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01673-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":149,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01673-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Riley M. Randolph, Sara Jubas, Li Gong, Raman Venkataramanan, Dhrita Khatri, Pamala A. Jacobson, David Metz, and Daniel J. Crona have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"De-identified data from previously published works were synthesized in this review; thus, ethics approval and patient consent were not required.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this review as no new data were created or analyzed. All information presented is compiled from the previously published literature and cited in the article.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Designed research: RMR, PAJ, DM, DJC. Performed literature search: RMR, SJ, LG, PAJ. Evaluated and synthesized data from selected publications: all authors. Analyzed data: RMR and DM. Wrote manuscript: all authors. Approved content for publication: all authors.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}